Pictilisib (GDC-0941)

Catalog No.S1065 Synonyms: RG7321

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Cited by 291 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )
Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )
Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )
Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )
Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )
Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )
Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )
Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )
Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )
Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )
PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )
J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MYnLbY5ie2ViQYPzZZk>		Ml24NUBp	NXfQTJNTTE2VTx?=	MlXQTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh\|ryP	NH:2XYYyQDd3NE[1OC=>
Sf9	MVXLbY5ie2ViQYPzZZk>		MVOxJIg>	M1;IdmROW09?	NIHweFRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEhUDFyNEetVkBufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	NIC3R2MyQDd3NE[1OC=>
Sf9	NH\K[lVMcW6jc3WgRZN{[Xl?		Mnq0NUBp	NXfl[YxETE2VTx?=	NWPiSnFnUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEV3NEWtT{BufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	NWOzOZozOTh5NUS2OVQ>
Sf9	NUHUWXN[U2mwYYPlJGF{e2G7		MV2xJIg>	NFTmbI5FVVOR	NWrxRYJDUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	NVToc4tiOTh5NUS2OVQ>
Sf9	NGO0R4RMcW6jc3WgRZN{[Xl?		MWmxJIg>	M2fqXmROW09?	M33yRmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIE>	MUOxPFc2PDZ3NB?=
MDA-MB-361	NXzSV5B6TnWwY4Tpc44hSXO\|YYm=		NFjk[mMzKGh?	M13OdGROW09?	M1LH[2lvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvODJ6IN88US=>	NX;TbYNwOTh5NUS2OVQ>
PC3	NXLFSolzTnWwY4Tpc44hSXO\|YYm=		MoDQNkBp	MkLNSG1UVw>?	NX:0d5cyUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gVGM{KGOnbHzzJJdqfGhiSVO1NEBw\iByLkCzO{DPxE1?	NVrCTo9TOTh5NUS2OVQ>
U87MG	NIr1dHZHfW6ldHnvckBCe3OjeR?=		NWTiXGhnOiCq	MYDEUXNQ	M4jFO2lvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gVHRGVi2wdXzsJIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiSVO1NEBw\iByLkC0OkDPxE1?	MUGxPFc2PDZ3NB?=
MDA-MB-361	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnXZPVYhcA>?	NFXOeotFVVOR	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlczKM7:TR?=	NUm2fVdbOTh5NUS2OVQ>
A2780	MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3Hvblk3KGh?	NWnUZ2YzTE2VTx?=	M1zvNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCSSVuzR2Eh[W6mIGDUSW4hdXW2YYTpc44hf2m2aDDJR\|UxKG:oIECuNVQh\|ryP	NWjkfJJ7OTh5NUS2OVQ>
PC3	NGf6U3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mo[yPVYhcA>?	NHHLbVJFVVOR	NV;0eWJCUUN3ME2wMlI5KM7:TR?=	Mm\3NVg4PTR4NUS=
U87MG	NWi3SYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV3JToV1QTZiaB?=	MkfnSG1UVw>?	MlHHTWM2OD1yLkm1JO69VQ>?	MnrJNVg4PTR4NUS=
Sf9	NXzQcJJnU2mwYYPlJGF{e2G7		MV2zNEBucW5?	NELvbXZFVVOR	M{fHO2lvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDhcY92dnRib3[gRXRRKGOxboP1cYVlKHerdHigTWM2OCCxZjCwMlA1OiEQvF2=	NXvNSpY3OjJ3NEizOFI>
RAW 264.7	MV\LbY5ie2ViQYPzZZk>		NHrzdW06OCCvaX6=	MofySG1UVw>?	MnG1TY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4zQThizszN	MmX6NlI2PDh\|NEK=
Sf9	NULOSZB[U2mwYYPlJGF{e2G7		MVOxJIg>		NEnYcIxKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[mW2YTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU1[5JINmdGy\|IIfpeIghUUN3MDDv[kAxNjBzNzFOwG0>	NHnafFUzOzV2ME[0OS=>
Sf9	NYWxfW42U2mwYYPlJGF{e2G7		M3\iR\|EhcA>?		MX;Jcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPL[IVtfGFiZYjwdoV{e2Wm	MXGyN\|U1ODZ2NR?=
Sf9	NFjoSHhMcW6jc3WgRZN{[Xl?		NXnse5VXOSCq		NV\JXHhOUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=>	M4DSbVI{PTRyNkS1
Sf9	MYDLbY5ie2ViQYPzZZk>		MYGxJIg>		MmHOTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4FteGijIHX4dJJme3OnZB?=	Mk\LNlM2PDB4NEW=
SKOV3	MXrLbY5ie2ViQYPzZZk>	MlnUNUDPxE1?	NGPadmUyKGh?	M3Luc2ROW09?	M{fkeGlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25?	NHj0TGozOzN4MEO0PC=>
MCF7	M3XyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHP4VlgyKM7:TR?=	MXe5OkBp	MWPEUXNQ	M{T0fmdKPTB;MD6wO\|AzKM7:TR?=	M{XSTVI{OzZyM{S4
SKOV3	NYLOcXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD2eHFsOSEQvF2=	MlPiPVYhcA>?	Ml7FSG1UVw>?	MXXHTVUxRTBwMUS3OkDPxE1?	MWSyN\|M3ODN2OB?=
PC3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmOyO\|IhcA>?	M1y2RmROW09?	MmroTWM2OD1yLkK4JO69VQ>?	NYjEfoZKOjF7OEG3NVQ>
MCF7.1	NWjQVnY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYPHfHhnPzJiaB?=	NU\5TIRQTE2VTx?=	MlrURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BJTVJ{IHflcoUhf2m2aDDJR\|UxKG:oIECuNlgh\|ryP	MUOyNVk5OTdzNB?=
MCF7-neo/Her2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2m3PFczKGh?	MXjEUXNQ	M4nTR2lEPTB;MD6yPUDPxE1?	NF;EbW4zOzZ4MkmwNy=>
MCF7-neo/Her2	M2jkcmtqdmG\|ZTDBd5NigQ>?				NW\6[Y1UUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txO	NVnnWHA{OjN4NkK5NFM>
PC3	NETpO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmnMO\|IhcA>?	MXTEUXNQ	NYTVeZlbTUN3ME2wMlM1KM7:TR?=	M1Xzb\|IyQTh3NkO5
MCF7.1	M2H4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M13BclczKGh?	M335dmROW09?	NXTvfIFqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFibYX0ZY51KHerdHigSWM2OCCxZjCwMlM6KM7:TR?=	M1zheFIyQTh3NkO5
PC3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn\mO\|IhcA>?	MnPHSG1UVw>?	NGTiWppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDk[YZq[2mnboSgbY4hWFSHTjD3bZRpKEmFNUCgc4YhOC5\|OTFOwG0>	MYqyNFA2ODZ4OR?=
MCF7.1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XKNlczKGh?	NIXEU4RFVVOR	NFLpS2xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDJR\|UxKG:oIECuN\|Qh\|ryP	M3vZPVIxODVyNk[5
MCF7.1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXf2b4hWPzJiaB?=		NFTLUIZGSzVyPUCuO\|Ih\|ryP	MUmyNFM1PjZ3Nh?=
NCI-H1975	NVO2T3hiS3m2b4TvfIlkKEG\|c3H5		MV23NkBp		MlfmTWM2OD1yLkK3JO69VQ>?	NFHOeGEzOzB3OUW0OS=>
H460	NXrHfpFsS3m2b4TvfIlkKEG\|c3H5		NYXufGRwPzJiaB?=		MX\JR\|UxRTBwOEeg{txO	Mmj1NlMxPTl3NEW=
HT-29	NUTUeJhqS3m2b4TvfIlkKEG\|c3H5		NED0Tmw4OiCq		NVnwXXNNUUN3ME2wMlY3KM7:TR?=	NVHBcIZyOjNyNUm1OFU>
HepG2	MYLDfZRwfG:6aXOgRZN{[Xl?		NV\6[VY3PzJiaB?=		NH3E[YZKSzVyPUGg{txO	NVy2cmx7OjNyNUm1OFU>
SGC7901	NGKxRZVEgXSxdH;4bYMhSXO\|YYm=		MnX2O\|IhcA>?		MWHJR\|UxRTFwODFOwG0>	NWHLXZA1OjNyNUm1OFU>
NCI-H226	M1fOWGN6fG:2b4jpZ{BCe3OjeR?=		Ml7oO\|IhcA>?		MYjJR\|UxRTJwOTFOwG0>	MmjRNlMxPTl3NEW=
A549	M1vM[GN6fG:2b4jpZ{BCe3OjeR?=		MkXaO\|IhcA>?		MX3JR\|UxRTZwOTFOwG0>	NGHN[3czOzB3OUW0OS=>
U87MG	NFTGTWREgXSxdH;4bYMhSXO\|YYm=		NUTjXGtVPzJiaB?=		NW\ibmdlUUN3ME23Mlc4KM7:TR?=	MYWyN\|A2QTV2NR?=
HBC4	M3HqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XYSYxw\0eLNUC9MVYvODNiTR?=	NHf3PVczOjN\|NkK0Oi=>
BSY1	NWTKRopnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zXXoxw\0eLNUC9MVYvQTBiTR?=	NUjMUJNWOjJ\|M{[yOFY>
HBC5	M3KwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHsc4dIUTVyPT22MlYxKE1?	NIPsfJYzOjN\|NkK0Oi=>
MCF7	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHsc4dIUTVyPT23MlM{KE1?	MnzyNlI{OzZ{NE[=
MDA-MB-231	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXsc4dIUTVyPT21MlQ3KE1?	NIXhSnMzOjN\|NkK0Oi=>
U251	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3sc4dIUTVyPT21MlUxKE1?	NWnhNYtMOjJ\|M{[yOFY>
SF268	M3z4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIOyfWVtd2eJSUWwQU02NjN7IF2=	NEPRbYwzOjN\|NkK0Oi=>
SF295	NXX5c4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjsc4dIUTVyPT22MlM4KE1?	NVLPPFg5OjJ\|M{[yOFY>
SF539	M2j2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;pcI9oT0l3ME2tOk42OCCP	NFXwflYzOjN\|NkK0Oi=>
SNB75	NE[1dmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDBSGltd2eJSUWwQU04NjFyIF2=	NW\sZpY1OjJ\|M{[yOFY>
SNB78	NIfXOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnLN5dRdG:pR1m1NF0uPi53MjDN	MWmyNlM{PjJ2Nh?=
HCC2998	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;sc4dIUTVyPT22MlI6KE1?	NYjKbo5sOjJ\|M{[yOFY>
KM12	NFTQfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;qV4xw\0eLNUC9MVUvPzZiTR?=	MVWyNlM{PjJ2Nh?=
HT-29	M1zNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2P1eYxw\0eLNUC9MVYvOzBiTR?=	MXSyNlM{PjJ2Nh?=
HCT15	NUPoNXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvacI9oT0l3ME2tOk4yOiCP	NWfjV3IxOjJ\|M{[yOFY>
HCT116	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE[zSnFtd2eJSUWwQU02Njh5IF2=	MUCyNlM{PjJ2Nh?=
NCI-H23	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHjeYNtd2eJSUWwQU02Njd\|IF2=	M{nGSVIzOzN4MkS2
NCI-H226	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLmboRtd2eJSUWwQU03NjJzIF2=	MX2yNlM{PjJ2Nh?=
NCI-H522	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPsc4dIUTVyPT22MlU5KE1?	NHn4WHozOjN\|NkK0Oi=>
NCI-H483	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Dy[4xw\0eLNUC9MVYvPTZiTR?=	MnHMNlI{OzZ{NE[=
A549	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHK4fm5td2eJSUWwQU03NjF3IF2=	MonINlI{OzZ{NE[=
DMS273	NXzkfHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXvcI9oT0l3ME2tOk41OyCP	MWmyNlM{PjJ2Nh?=
DMS114	MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jmWIxw\0eLNUC9MVUvQTJiTR?=	NI\rSYczOjN\|NkK0Oi=>
LOXIMVI	NWjDbmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknWcI9oT0l3ME2tOk4zQSCP	MnzsNlI{OzZ{NE[=
OVCAR3	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHsc4dIUTVyPT22MlcyKE1?	M1zvblIzOzN4MkS2
OVCAR4	NVS4WnFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmG0cI9oT0l3ME2tOU44PiCP	M2e5[lIzOzN4MkS2
OVCAR5	MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEKyNVRtd2eJSUWwQU03NjJ4IF2=	NWew[GJrOjJ\|M{[yOFY>
OVCAR8	NXHrbmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\Pfoxw\0eLNUC9MVUvPzNiTR?=	MlTzNlI{OzZ{NE[=
SKOV3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPKcI9oT0l3ME2tOk42OiCP	NVrS[nJnOjJ\|M{[yOFY>
RXF631L	NEnTfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnlcI9oT0l3ME2tOk45QCCP	NXLR[YFGOjJ\|M{[yOFY>
ACHN	NV2xfHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHoWIZtd2eJSUWwQU03NjB5IF2=	NVPwSnd5OjJ\|M{[yOFY>
St-4	NW\RU2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Txd4xw\0eLNUC9MVUvPTZiTR?=	MkfaNlI{OzZ{NE[=
MKN1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{G3fIxw\0eLNUC9MVcvODhiTR?=	MoThNlI{OzZ{NE[=
MKN7	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPsc4dIUTVyPT22MlUxKE1?	NYX3T4ZPOjJ\|M{[yOFY>
MKN28	M3G1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTsc4dIUTVyPT21MlUzKE1?	NF3z[YwzOjN\|NkK0Oi=>
MKN45	NHO5eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TRUoxw\0eLNUC9MVYvPTViTR?=	M1XDWFIzOzN4MkS2
MKN74	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYSzXGM{dG:pR1m1NF0uPi5yMjDN	MVqyNlM{PjJ2Nh?=
DU145	NHi4dIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;5fFRtd2eJSUWwQU02Njh3IF2=	NVPBUIc2OjJ\|M{[yOFY>
PC3	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfNeWRvdG:pR1m1NF0uPi54NjDN	MWmyNlM{PjJ2Nh?=
ES5	NEn4TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jRNmlEPTB;NUCuNlEhdk1?	Mon3V2FPT0WU
HH	NFX1c\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXWTWM2OD1zMUGuNFghdk1?	NGDx[opUSU6JRWK=
MHH-PREB-1	NVHqNXFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfoPXpKSzVyPUGxOE4{KG6P	MkPOV2FPT0WU
NCI-H1770	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETMPVRKSzVyPUGyN{45PiCwTR?=	M3XwS3NCVkeHUh?=
HuO9	NY\mToFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jVXmlEPTB;MkC2MlAzKG6P	Mm\ZV2FPT0WU
HAL-01	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTJyNj63N{BvVQ>?	MXTTRW5ITVJ?
NOS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TYW2lEPTB;MkGxMlgzKG6P	Mn;MV2FPT0WU
HGC-27	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn34TWM2OD1{MUKuOVchdk1?	MXzTRW5ITVJ?
NB69	NVHMTnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfoVYJKSzVyPUK0OU4zPyCwTR?=	NGfsSHlUSU6JRWK=
RS4-11	M2Tq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XoSmlEPTB;Mk[xMlc3KG6P	NXTrbVA1W0GQR1XS
DOK	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnK5TWM2OD1\|MEGuO{BvVQ>?	NVP2T2VKW0GQR1XS
LB2241-RCC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTNyMz64OEBvVQ>?	NH\rVHhUSU6JRWK=
NCI-H1623	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zGV2lEPTB;M{C0MlA5KG6P	NGLxUJNUSU6JRWK=
YH-13	M3LyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonHTWM2OD1\|MESuN\|Ihdk1?	MYXTRW5ITVJ?
BPH-1	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3KfotuUUN3ME2zNVQhdk1?	NGfCN4lUSU6JRWK=
AN3-CA	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M164SmlEPTB;M{SwMlM4KG6P	M1TMNnNCVkeHUh?=
ES7	NVPH[5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTN2MT65PUBvVQ>?	M4XvSXNCVkeHUh?=
MDA-MB-175-VII	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm3VWZMUUN3ME2zOVIvQTJibl2=	MoT0V2FPT0WU
GAMG	NETEcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTN5MD64OUBvVQ>?	NETkZ29USU6JRWK=
CHL-1	M3v5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PPbmlEPTB;M{e4MlY2KG6P	M2ftOHNCVkeHUh?=
NB7	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XBWGlEPTB;M{i5Mlg{KG6P	NUHBXlRjW0GQR1XS
MFE-280	M1nRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTRzOD6yJI5O	MV7TRW5ITVJ?
HL-60	NHTZ[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTINVBCUUN3ME20NlUvPzVibl2=	Mlm5V2FPT0WU
GCIY	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n1bmlEPTB;NEOzMlghdk1?	NWW2UnJ3W0GQR1XS
MDA-MB-361	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELybZZKSzVyPUSzPU4yOyCwTR?=	NFvmTlBUSU6JRWK=
LXF-289	M3z5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEm2RVFKSzVyPUS0PE4zPyCwTR?=	M33lW3NCVkeHUh?=
NBsusSR	NF60NmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu0R4lKSzVyPUS4PE45PSCwTR?=	MmraV2FPT0WU
KU-19-19	NXHXVIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTVzNj6wO{BvVQ>?	M13ERnNCVkeHUh?=
A204	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknETWM2OD13MkKuN\|Mhdk1?	MkezV2FPT0WU
LB1047-RCC	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUS3R3diUUN3ME21NlIvQTNibl2=	NGX4XY9USU6JRWK=
COLO-684	NELCUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTV{Mz6xNUBvVQ>?	Ml:2V2FPT0WU
PA-1	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjH[FlmUUN3ME21N\|IvPDFibl2=	M3fRfXNCVkeHUh?=
MG-63	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LzPGlEPTB;NUSxMlEyKG6P	MmLJV2FPT0WU
BHT-101	M2fGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fxcGlEPTB;NUS0Mlk1KG6P	NV3W[IhXW0GQR1XS
NKM-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTV7Mz6wPUBvVQ>?	MnfHV2FPT0WU
T47D	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[2WmlEPTB;NUm3MlU3KG6P	NXjuWm1QW0GQR1XS
MOLT-4	M2P3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PVdGlEPTB;NkKzMlYzKG6P	M2nBenNCVkeHUh?=
IGROV-1	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fwc2lEPTB;NkO0MlMyKG6P	NYmyc2xnW0GQR1XS
ES4	NX62SVdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWC3bYdWUUN3ME22N\|kvPTRibl2=	MV\TRW5ITVJ?
HuO-3N1	NWLpc29OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTZ2Mj6zPEBvVQ>?	M4r1NnNCVkeHUh?=
NEC8	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrOTWM2OD14NUOuOVchdk1?	Mne2V2FPT0WU
HO-1-N-1	NGPX[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfETWM2OD14NUmuNVchdk1?	NHnZSYFUSU6JRWK=
EPCL-272H	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfYcWRsUUN3ME22PFcvOjFibl2=	MV3TRW5ITVJ?
D-263MG	NH3xcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;HTWM2OD15MUiuNUBvVQ>?	MUfTRW5ITVJ?
MV-4-11	NEDzeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjlTlRMUUN3ME23NlQvOzFibl2=	MUTTRW5ITVJ?
SK-NEP-1	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPPc3c6UUN3ME23NlUvQTRibl2=	NUDoTpJWW0GQR1XS
SW872	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PPV2lEPTB;N{K3Mlg6KG6P	NXnTcotRW0GQR1XS
P30-OHK	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj4[3NKSzVyPUezNE44OSCwTR?=	M2DIe3NCVkeHUh?=
OMC-1	M3TsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3ZWVRGUUN3ME23OVEvODlibl2=	MW\TRW5ITVJ?
LoVo	NX\mPWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofXTWM2OD15N{euPUBvVQ>?	MWPTRW5ITVJ?
LNCaP-Clone-FGC	NXrqbpNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjucYV1UUN3ME23PVYvOzRibl2=	M{\WO3NCVkeHUh?=
L-363	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXEdG9JUUN3ME23PVgvPDJibl2=	NYC5SIx{W0GQR1XS
ES8	NIjLN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mln5TWM2OD16MUCuOVIhdk1?	NGTWNlZUSU6JRWK=
697	NGDzb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrjTmtKSzVyPUizNU42PSCwTR?=	MmnKV2FPT0WU
HSC-3	NXOyXVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[3b2lEPTB;OEO5MlU1KG6P	NILTenRUSU6JRWK=
H4	NFuzOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7CR2VKSzVyPUi1NE45PSCwTR?=	NVrUfYxtW0GQR1XS
QIMR-WIL	NY\Qd44zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LIV2lEPTB;OE[1MlIhdk1?	M2L3T3NCVkeHUh?=
OAW-42	M1PKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\L[2lEPTB;OEeyMlE6KG6P	MWXTRW5ITVJ?
MCF7	M2nETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPCTotxUUN3ME24PVgvPTlibl2=	MlXkV2FPT0WU
SCC-25	M2HaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTlzND6xPUBvVQ>?	NXPD[3FpW0GQR1XS
NCI-H1563	NHqzS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX2TWM2OD17MUWuPVkhdk1?	NIHTZ5FUSU6JRWK=
OVCAR-5	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrCOYVsUUN3ME25OFAvOTdibl2=	NXvHXIlkW0GQR1XS
HDLM-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NET6NHZKSzVyPUm0PU4zKG6P	MoGxV2FPT0WU
NB5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{G2RWlEPTB;OUW2MlYhdk1?	NYfabHo2W0GQR1XS
NCI-H292	NEOwdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPHeoNlUUN3ME25O\|QvOzJibl2=	MVHTRW5ITVJ?
A101D	NHPaV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfBTWM2OD17OUCuNVkhdk1?	MX;TRW5ITVJ?
NCI-H1648	M{fzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF:3PIxKSzVyPUm5PE42OSCwTR?=	NH\XfZpUSU6JRWK=
EKVX	NV\rb4x[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPCTWM2OD1zLkCxNlkh\|ryP	NHzncpBUSU6JRWK=
SW1710	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES4VYhKSzVyPUGuNFQzOzNizszN	NXS1bIg3W0GQR1XS
WM-115	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfWTWM2OD1zLkC2OlU3KM7:TR?=	NXqyVFBCW0GQR1XS
CAL-54	NECzfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfzdYM1UUN3ME2xMlA4ODhzIN88US=>	Ml3XV2FPT0WU
TGBC24TKB	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTnTWM2OD1zLkC4NFQ2KM7:TR?=	MkjrV2FPT0WU
NCI-H520	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTFwMEi5Olch\|ryP	NUfKe4ozW0GQR1XS
D-423MG	NETIeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvvR4FxUUN3ME2xMlA6QTZ{IN88US=>	NIfqW2NUSU6JRWK=
BFTC-905	NH;4SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTFwMUO0OFkh\|ryP	MXHTRW5ITVJ?
HT	NXLmSlYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWL3ZlZUUUN3ME2xMlE{PDd6IN88US=>	NED4[lNUSU6JRWK=
CTB-1	NVrseohNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTFwMUSyPVMh\|ryP	NYqwU2drW0GQR1XS
Hs-578-T	NH7oeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{mw[mlEPTB;MT6xPVU3PSEQvF2=	NFzVRYFUSU6JRWK=
HuH-7	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS0d5RKSzVyPUGuNlA6PDlizszN	M1zYWXNCVkeHUh?=
LB996-RCC	NUDDVph7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXj2dog{UUN3ME2xMlIzOTd5IN88US=>	NHLOT3dUSU6JRWK=
KYSE-270	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LuV2lEPTB;MT6yPVc{PCEQvF2=	NWS4WmFjW0GQR1XS
A4-Fuk	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofmTWM2OD1zLkK5PVk{KM7:TR?=	M4j4XHNCVkeHUh?=
A498	M1TJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PSSGlEPTB;MT6zNFQ4PCEQvF2=	NXXS[5lLW0GQR1XS
SK-MEL-1	NVPPXFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\GTWM2OD1zLkOwOlc6KM7:TR?=	MnnMV2FPT0WU
AU565	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXOWINVUUN3ME2xMlMyQDZ\|IN88US=>	NWrVO3NvW0GQR1XS
Saos-2	M1PnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37kR2lEPTB;MT6zN\|IxPSEQvF2=	M1v6d3NCVkeHUh?=
A549	NFPYdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjKbYhyUUN3ME2xMlM6QTdizszN	MlvNV2FPT0WU
BFTC-909	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jnR2lEPTB;MT60N\|MxPSEQvF2=	Ml;zV2FPT0WU
MDA-MB-415	NGPLWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHlTWM2OD1zLkS4OlkzKM7:TR?=	NXPnR4ZUW0GQR1XS
639-V	M4LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XpNmlEPTB;MT61NFI1PSEQvF2=	M{DLSXNCVkeHUh?=
A704	NUPtRXdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moe1TWM2OD1zLkWwO\|g2KM7:TR?=	MVLTRW5ITVJ?
PANC-03-27	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwNUG0NFgh\|ryP	MY\TRW5ITVJ?
SK-MEL-28	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLXbI1vUUN3ME2xMlU3ODh3IN88US=>	MmGyV2FPT0WU
Ramos-2G6-4C10	NY[3Vm95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTFwNkC3OFYh\|ryP	Mon2V2FPT0WU
HuP-T4	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzPXlRKSzVyPUGuOlA4PzhizszN	MnXoV2FPT0WU
VA-ES-BJ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\a[WlEPTB;MT62NVI4KM7:TR?=	NVvXOldHW0GQR1XS
EFM-19	NU\HPY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O2VWlEPTB;MT62NVgyKM7:TR?=	M3TuUXNCVkeHUh?=
G-401	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTCTWM2OD1zLk[yNVY1KM7:TR?=	NHvNVG9USU6JRWK=
D-566MG	NYrHT3JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLndINKSzVyPUGuOlI2OyEQvF2=	MlviV2FPT0WU
JVM-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTMTWM2OD1zLk[0PFc2KM7:TR?=	NXHNR4FsW0GQR1XS
TK10	NHzubJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHPTWM2OD1zLk[3NFg{KM7:TR?=	MonRV2FPT0WU
BT-20	NYLPWYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;LWmlZUUN3ME2xMlY5QTB{IN88US=>	NYPrbXpTW0GQR1XS
EGI-1	MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTFwOES3NFEh\|ryP	NX:w[m5CW0GQR1XS
EW-16	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWiycphFUUN3ME2xMlg2OTh{IN88US=>	M4j6R3NCVkeHUh?=
NCI-H2228	M4TYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFG4N5dKSzVyPUGuPFUzODNizszN	M2HBNHNCVkeHUh?=
BB49-HNC	NHj1UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\OVohmUUN3ME2xMlg5Pjl{IN88US=>	MWrTRW5ITVJ?
G-402	NH3L[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli4TWM2OD1zLki5O\|k4KM7:TR?=	MYDTRW5ITVJ?
NCI-H526	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXEOXQ3UUN3ME2xMlkyOzlizszN	M4H4SnNCVkeHUh?=
ME-180	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfDVGlKSzVyPUGuPVM1PzdizszN	NHm2[3dUSU6JRWK=
PFSK-1	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXJTWM2OD1zLkm0OFU5KM7:TR?=	MkPWV2FPT0WU
TYK-nu	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;4TWM2OD1zLkm1PFI{KM7:TR?=	M{HGN3NCVkeHUh?=
HOS	NIr1folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDrTWM2OD1zLkm3PVQ5KM7:TR?=	NVntb5NWW0GQR1XS
T98G	M1jjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTSRmdKSzVyPUGuPVkxODZizszN	M1nUXnNCVkeHUh?=
SK-MES-1	NUfI[HR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHyy[YRKSzVyPUKuNFE{OzJizszN	M2Dqd3NCVkeHUh?=
SNB75	MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljwTWM2OD1{LkCxOVQyKM7:TR?=	NVrye5NiW0GQR1XS
LAMA-84	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLEWVlMUUN3ME2yMlAzPjh7IN88US=>	MWrTRW5ITVJ?
CAL-39	NVvSS3ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJwMEOyPEDPxE1?	MonnV2FPT0WU
LOXIMVI	NYPXb3RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJwMESwPFQh\|ryP	NES2UohUSU6JRWK=
NH-12	M2XBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfFN5dKSzVyPUKuNFU1OjRizszN	NV;ue3ZrW0GQR1XS
NCI-H1048	NVu3bpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH5TWM2OD1{LkGwOVIh\|ryP	MX\TRW5ITVJ?
KS-1	M1H6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moe3TWM2OD1{LkGxNFAyKM7:TR?=	MY\TRW5ITVJ?
NCI-N87	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHFeGpSUUN3ME2yMlE{Ozh2IN88US=>	NGHMb\|BUSU6JRWK=
CHP-212	NXnXcYhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTVWGN{UUN3ME2yMlE5PDR{IN88US=>	Mk\DV2FPT0WU
HCC1419	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\MOXVUUUN3ME2yMlIyOTF3IN88US=>	M3fjbXNCVkeHUh?=
ES1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJwMkGzNlYh\|ryP	NGDtVY9USU6JRWK=
NCI-H2030	NWTxWphvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zpRmlEPTB;Mj6yOFEzOyEQvF2=	M2LpNXNCVkeHUh?=
EW-22	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJwMkWwOlch\|ryP	M{DHRnNCVkeHUh?=
A431	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmniTWM2OD1{LkK3N\|U1KM7:TR?=	NUDtPXhmW0GQR1XS
SF126	NIjWb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJwM{C2NlUh\|ryP	NYDaNY1pW0GQR1XS
SF295	NVL0XHZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJwM{G1NlQh\|ryP	Mkj4V2FPT0WU
D-502MG	M2PS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGKzcoVKSzVyPUKuN\|I1PjFizszN	MYXTRW5ITVJ?
HCC2157	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrtSGxKSzVyPUKuN\|I6OjdizszN	M4G4dnNCVkeHUh?=
D-283MED	M4SzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[0V2xlUUN3ME2yMlM2QTJ4IN88US=>	M{DpSXNCVkeHUh?=
SNU-423	NGPZcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJwNECxO\|Eh\|ryP	MV3TRW5ITVJ?
SK-LU-1	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPnc5FZUUN3ME2yMlQ1PTh4IN88US=>	NFH5XoxUSU6JRWK=
22RV1	MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfXboZKSzVyPUKuOFU3OTdizszN	MYfTRW5ITVJ?
SW1088	M4PRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLB[ZpbUUN3ME2yMlQ6OjF\|IN88US=>	Mn\EV2FPT0WU
HT-3	NWS3b5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTmW2RIUUN3ME2yMlQ6OjV7IN88US=>	NWXFO2V3W0GQR1XS
NCI-H1666	NVGyUZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJwNUGxNFQh\|ryP	M{W2XHNCVkeHUh?=
EM-2	NUKxbVJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljyTWM2OD1{LkWxNVY6KM7:TR?=	MVPTRW5ITVJ?
SNU-449	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jtPGlEPTB;Mj61O\|AyPCEQvF2=	Ml7WV2FPT0WU
786-0	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJwNUmyN\|gh\|ryP	MkTsV2FPT0WU
SKG-IIIa	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnGfYZKSzVyPUKuOlU6OzlizszN	M3ryO3NCVkeHUh?=
MEL-HO	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJwNke2N\|Qh\|ryP	MYTTRW5ITVJ?
LCLC-97TM1	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HJe2lEPTB;Mj62PVI3PyEQvF2=	NUjJOmJPW0GQR1XS
MKN7	NWruVYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;ndmlEPTB;Mj63NFc2PCEQvF2=	M3:3eHNCVkeHUh?=
5637	NYqzOoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzkbVBKSzVyPUKuO\|ExOzVizszN	NE\oeplUSU6JRWK=
HOP-92	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\FfmFKSzVyPUKuO\|Q4OTdizszN	NWfSN3QxW0GQR1XS
MDA-MB-157	MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3iSXh5UUN3ME2yMlgzODJ\|IN88US=>	MYTTRW5ITVJ?
NB12	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjSTWM2OD1{Lki0PVE1KM7:TR?=	MWnTRW5ITVJ?
DMS-273	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvGTWM2OD1{Lki2OFch\|ryP	MX3TRW5ITVJ?
HCC70	NHzDNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LLW2lEPTB;Mj64OlU5QSEQvF2=	Mlu3V2FPT0WU
YKG-1	M{TIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXaenhKSzVyPUOuNFM4QDdizszN	NEj4W3ZUSU6JRWK=
NCI-H28	NVjZSoljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jHZWlEPTB;Mz6wOVI6OSEQvF2=	M2n2O3NCVkeHUh?=
HN	MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjhVXVqUUN3ME2zMlA3PjN4IN88US=>	NE\heZhUSU6JRWK=
HT-1080	M1HLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[4VoVKSzVyPUOuNFg3ODZizszN	MWnTRW5ITVJ?
HPAF-II	NEK3XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{WxOGlEPTB;Mz6xNFA3QCEQvF2=	NV;5ZVJKW0GQR1XS
U-2-OS	NV7kTGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nFXmlEPTB;Mz6xN\|c5OiEQvF2=	NXriSWwyW0GQR1XS
SNU-387	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoKwTWM2OD1\|LkG2N\|Y1KM7:TR?=	NHW0N3RUSU6JRWK=
Becker	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXr4R3VQUUN3ME2zMlE3QDB6IN88US=>	NY\JWXY2W0GQR1XS
BHY	NILFeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TONWlEPTB;Mz6yOVU4OSEQvF2=	Mmq2V2FPT0WU
HTC-C3	NFK4ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHVXotKSzVyPUOuNlk{PTJizszN	MmfQV2FPT0WU
M14	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jsdWlEPTB;Mz6zNFY3OyEQvF2=	M1PoV3NCVkeHUh?=
COR-L23	M4joe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTQN5pKSzVyPUOuN\|czPzlizszN	MUXTRW5ITVJ?
C32	M{jmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTNwNEG1NFgh\|ryP	NXG4SpRHW0GQR1XS
Mewo	NFTZfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTKfllYUUN3ME2zMlQzOTh{IN88US=>	MoPyV2FPT0WU
TE-8	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3McGdKSzVyPUOuOFgzPTlizszN	NH:1ZYZUSU6JRWK=
RPMI-2650	NYjWNG13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV20cWllUUN3ME2zMlYxPjN5IN88US=>	M2\4R3NCVkeHUh?=
AGS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEO0OndKSzVyPUOuOlI1PjRizszN	MXPTRW5ITVJ?
MZ2-MEL	NEPuRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXxNG1TUUN3ME2zMlY3OTN6IN88US=>	NFzKcGhUSU6JRWK=
Calu-3	NGfIfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNwN{GyPFch\|ryP	MnHqV2FPT0WU
SJSA-1	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TqW2lEPTB;Mz63NVMyPSEQvF2=	MUjTRW5ITVJ?
SW962	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rVTGlEPTB;Mz63NlY{PiEQvF2=	NXzIfJpvW0GQR1XS
PC-14	M3q4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PyeWlEPTB;Mz63N\|IzOiEQvF2=	M3[3[HNCVkeHUh?=
SW1573	M1ztZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PWTWlEPTB;Mz63OVM1QCEQvF2=	MWPTRW5ITVJ?
769-P	M1\afmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULXOnJvUUN3ME2zMlgzPzR\|IN88US=>	NGr3RmJUSU6JRWK=
KNS-62	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISxe5FKSzVyPUOuPVI{OzhizszN	M3\J[3NCVkeHUh?=
NCI-H747	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnQb4ZKSzVyPUSuNFU3OzhizszN	NYPvTlVKW0GQR1XS
LN-405	NXG0O\|ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHXTWM2OD12LkG1O\|I5KM7:TR?=	NH7VbZlUSU6JRWK=
OVCAR-8	M33ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXWS3drUUN3ME20MlIzPTR\|IN88US=>	NIWyUFVUSU6JRWK=
DMS-114	NInFclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:yPY5KSzVyPUSuNlM5QTFizszN	NGm2Z3ZUSU6JRWK=
NCI-H2126	M3m2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXP3[o9xUUN3ME20MlI1PTV6IN88US=>	NV7SSHNWW0GQR1XS
TCCSUP	NYDrOoFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjZc5RKSzVyPUSuNlQ4QDhizszN	MW\TRW5ITVJ?
SK-N-FI	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTRwMkWzN\|Ih\|ryP	NIXuNW9USU6JRWK=
HCE-4	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHqTWM2OD12LkK3NVk4KM7:TR?=	NUXyPFQ{W0GQR1XS
DK-MG	MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTRwM{CzPUDPxE1?	NVvnVFhTW0GQR1XS
RO82-W-1	NVX3T5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTRwM{K1PFQh\|ryP	MmHXV2FPT0WU
A2780	NW\oPVdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkflTWM2OD12LkO2OlgzKM7:TR?=	NWThRVdxW0GQR1XS
ETK-1	NWDuOFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2i4VmlEPTB;ND6zO\|A2OiEQvF2=	MV7TRW5ITVJ?
FADU	NHnL[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XBcmlEPTB;ND6zO\|Q3PyEQvF2=	MmSwV2FPT0WU
CAL-12T	NHjtU\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTS[mpUUUN3ME20MlQyPDF\|IN88US=>	MXzTRW5ITVJ?
647-V	NVP5UnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn:3TWM2OD12LkS0NFIzKM7:TR?=	MkDaV2FPT0WU
TGBC1TKB	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfPWXh3UUN3ME20MlQ2OTF\|IN88US=>	NX7D[nl2W0GQR1XS
LU-99A	M2nEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk[xTWM2OD12LkS2NFYh\|ryP	Mn7kV2FPT0WU
CAL-33	M37CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTRwNUK0OVYh\|ryP	M3HhXHNCVkeHUh?=
LU-134-A	M1roR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfuTWM2OD12LkWyO\|Q2KM7:TR?=	MlPhV2FPT0WU
NCI-H1355	M37ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXRZ2xqUUN3ME20MlU2OTR4IN88US=>	MnXvV2FPT0WU
RPMI-7951	NGXK[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjZTIVEUUN3ME20MlU4ODB{IN88US=>	MXnTRW5ITVJ?
TE-1	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXkZ4FYUUN3ME20MlY3OTR\|IN88US=>	MXLTRW5ITVJ?
OE33	M3vjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjVSmo3UUN3ME20MlcxPTFzIN88US=>	MVnTRW5ITVJ?
CAL-51	NXz0ZVgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPTTWM2OD12LkexNFgzKM7:TR?=	MVLTRW5ITVJ?
SW1783	NIruNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUThPGE{UUN3ME20Mlc2OzB6IN88US=>	NIXpPGFUSU6JRWK=
BT-474	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzTUWE4UUN3ME20Mlc3Ozh2IN88US=>	NY\3PHV2W0GQR1XS
KYSE-520	M3Oz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF:4TI9KSzVyPUSuPFc{QTJizszN	NYrERlg3W0GQR1XS
8-MG-BA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnS1TWM2OD12Lki4OVU4KM7:TR?=	M3nNcHNCVkeHUh?=
IA-LM	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:w[It4UUN3ME20Mlk6PDN3IN88US=>	MXLTRW5ITVJ?
SW954	NGixV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4noZWlEPTB;ND65PVQ1OyEQvF2=	NUPFRppsW0GQR1XS
RPMI-8226	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\GOGpKSzVyPUWuNFU1PjFizszN	M2nZRXNCVkeHUh?=
MKN1	NH;ZUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;oTWM2OD13LkC3PVI4KM7:TR?=	MUTTRW5ITVJ?
A375	M{CyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nURmlEPTB;NT6wPVI2PiEQvF2=	NILpUGNUSU6JRWK=
8305C	M4r3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXISplKSzVyPUWuNFk5QDdizszN	M2e0THNCVkeHUh?=
CAL-62	M{DpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTVwMUiyOVkh\|ryP	MmfKV2FPT0WU
NB10	M3PKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvNV\|hKSzVyPUWuNlI4PDRizszN	NUm5SFdnW0GQR1XS
OC-314	NUK0VGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHzTWM2OD13LkO3OFQ1KM7:TR?=	MXfTRW5ITVJ?
PSN1	NULUTFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DpbGlEPTB;NT6zPFI5PiEQvF2=	MVLTRW5ITVJ?
GR-ST	NXPwVWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LtOGlEPTB;NT6zPFMzOiEQvF2=	Mnf4V2FPT0WU
P12-ICHIKAWA	M{L2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTVwNECxJO69VQ>?	MorOV2FPT0WU
NCI-H1092	NHLLS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojWTWM2OD13LkSxNVQ5KM7:TR?=	Mm\hV2FPT0WU
SCC-4	NYD5RW13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLaT2hDUUN3ME21MlQyOzV3IN88US=>	Mmn6V2FPT0WU
TE-6	NWfwSGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnKcGNIUUN3ME21MlQyQDF4IN88US=>	M2HF[HNCVkeHUh?=
DOHH-2	NYjBW2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{m4OGlEPTB;NT60NlI1QCEQvF2=	M3XvR3NCVkeHUh?=
SW684	NY\EV29zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrGb21KSzVyPUWuOlY{QDVizszN	NXjRfGNzW0GQR1XS
CP50-MEL-B	M4D0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHHdWRKSzVyPUWuOlg3QDRizszN	NHTZb3BUSU6JRWK=
UM-UC-3	NFL1VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jrUmlEPTB;NT63NlI{OSEQvF2=	MV7TRW5ITVJ?
LC-2-ad	M{Xvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XpWWlEPTB;NT63PFI2OSEQvF2=	Mkf4V2FPT0WU
PC-3	NUXUd5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XhNmlEPTB;NT65NVYyPSEQvF2=	M4PLR3NCVkeHUh?=
CAN	NX3uVFg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;vTWM2OD13LkmyPFIh\|ryP	MX7TRW5ITVJ?
ESS-1	NUmzVINMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTVwOUe4Olkh\|ryP	MWnTRW5ITVJ?
ATN-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnryTWM2OD14LkC1OVY5KM7:TR?=	NITjco1USU6JRWK=
BxPC-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTZwMEiyNVkh\|ryP	NVy4U5ZbW0GQR1XS
KYSE-150	NI\LenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrFTWM2OD14LkGyOFc3KM7:TR?=	NFfkbnpUSU6JRWK=
RPMI-8866	M2XrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHIeWtCUUN3ME22MlE6OTZ\|IN88US=>	MXXTRW5ITVJ?
SW780	NU\nflJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jjU2lEPTB;Nj6yNFQzKM7:TR?=	NUW0elU5W0GQR1XS
A388	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX62SYt1UUN3ME22MlI{OTF3IN88US=>	NV7KNpc{W0GQR1XS
NCI-H1437	M1rZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\BRWlEPTB;Nj6yOFA4OyEQvF2=	MoKwV2FPT0WU
NCI-H1755	NXnPNVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTZwM{[2NVIh\|ryP	NIKzUFBUSU6JRWK=
LS-123	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\ucmlEPTB;Nj60NFUzOSEQvF2=	NGfhWI9USU6JRWK=
CaR-1	M{\Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX4PVhKSzVyPU[uOFY{PzNizszN	MXrTRW5ITVJ?
RT-112	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHDTWM2OD14Lk[wN\|M5KM7:TR?=	MUnTRW5ITVJ?
CGT	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLtcXdNUUN3ME22Mlc{PjhzIN88US=>	Mkm1V2FPT0WU
SW626	NXLBOmJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPGTWM2OD14LkezPVQ3KM7:TR?=	Mon1V2FPT0WU
AsPC-1	NITkOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37UWmlEPTB;Nj63OFUxPyEQvF2=	M2noZ3NCVkeHUh?=
SBC-5	NXKzU21sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFKybVZKSzVyPU[uPVczQTdizszN	MnezV2FPT0WU
SF539	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHh[5FSUUN3ME22Mlk6OzN\|IN88US=>	NEftPWdUSU6JRWK=
TI-73	NHPh[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXf2bYlLUUN3ME23MlA3Ojh3IN88US=>	MlPaV2FPT0WU
MHH-ES-1	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLqWlFUUUN3ME23MlA4PzZ{IN88US=>	NYrJUZBzW0GQR1XS
KYSE-510	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz5TWM2OD15LkC4OFMzKM7:TR?=	NX\MW4RjW0GQR1XS
EW-1	NVfJcXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHQTWM2OD15LkO2PVk3KM7:TR?=	NHjVd2dUSU6JRWK=
SK-OV-3	NGW2WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGGxdm5KSzVyPUeuN\|k1OzJizszN	MmTyV2FPT0WU
MC-IXC	NH7J[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj3doVKSzVyPUeuOFE6PzJizszN	MWfTRW5ITVJ?
HSC-2	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnvOm9kUUN3ME23MlQzPzB3IN88US=>	MYDTRW5ITVJ?
NCI-H2342	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTdwNUG0PUDPxE1?	NIjJfYVUSU6JRWK=
NCI-H1792	M2TCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnNfphKSzVyPUeuOVE4OTFizszN	MkPNV2FPT0WU
HT-1376	NEXJboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTdwOEe3O\|gh\|ryP	MnTqV2FPT0WU
EW-13	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\hfGlEPTB;Nz64PVk4PyEQvF2=	NWH2W2ZqW0GQR1XS
no-11	Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmftTWM2OD15LkmwNVc1KM7:TR?=	MlLCV2FPT0WU
Daoy	NEPBfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzkTWM2OD15Lkm0N\|IyKM7:TR?=	MXnTRW5ITVJ?
COLO-800	NWDGZo5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrVWFdVUUN3ME24MlA1OTZ{IN88US=>	MlG1V2FPT0WU
GB-1	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H1OGlEPTB;OD6wOlU3PSEQvF2=	NHnYRVJUSU6JRWK=
SJRH30	NYDoVGFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLITWM2OD16LkG1PFc5KM7:TR?=	Mk\HV2FPT0WU
NCI-H2291	MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHoN2xKSzVyPUiuNlkyQDdizszN	NIHwcW9USU6JRWK=
J82	MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jLdmlEPTB;OD6yPVQ6OSEQvF2=	MYTTRW5ITVJ?
NCI-H596	NX\IWG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHBU3VKSzVyPUiuN\|E1PTNizszN	M1LzTnNCVkeHUh?=
RERF-LC-MS	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlS4TWM2OD16LkO0PFU3KM7:TR?=	M1\LcXNCVkeHUh?=
RH-18	NH3ycpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPx[WdKSzVyPUiuN\|UxPDZizszN	M3v4eXNCVkeHUh?=
SW48	NWewWYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRThwNUm0OVMh\|ryP	M4TsVnNCVkeHUh?=
RD	NWPXW4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13tV2lEPTB;OD61PVM6OSEQvF2=	NX7FVllJW0GQR1XS
MS-1	NHTYfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG2TWM2OD16Lk[xN\|g4KM7:TR?=	NHXubphUSU6JRWK=
ES6	NH;1XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PRbmlEPTB;OD63N\|EyQSEQvF2=	M3zUUnNCVkeHUh?=
TE-12	M1XZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRThwN{e1NFUh\|ryP	Mkj6V2FPT0WU
DBTRG-05MG	M4LoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRThwOUGyNVch\|ryP	M4jGdHNCVkeHUh?=
KINGS-1	NH[wOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPHOpYyUUN3ME24MlkzQTN6IN88US=>	MnvhV2FPT0WU
HLE	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LVWWlEPTB;OD65N\|c5PSEQvF2=	Moq0V2FPT0WU
MHH-NB-11	NGHjUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PPcWlEPTB;OT6wNVg{QSEQvF2=	Mn;1V2FPT0WU
U-87-MG	NIrQRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDQTWM2OD17LkK0N\|IyKM7:TR?=	MorGV2FPT0WU
MN-60	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjKcItsUUN3ME25MlI1PTR{IN88US=>	M{fRO3NCVkeHUh?=
SAS	NHzQXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nqemlEPTB;OT6yOVU5OSEQvF2=	MnvJV2FPT0WU
NCI-H446	M{nqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfZTWM2OD17LkO2NUDPxE1?	NULyNFZJW0GQR1XS
C-33-A	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTlwNEO5PFgh\|ryP	MmHyV2FPT0WU
RXF393	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTlwNEewNFIh\|ryP	M2i1NHNCVkeHUh?=
CGTH-W-1	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmD3TWM2OD17LkS5N\|g1KM7:TR?=	M{XOdXNCVkeHUh?=
RCM-1	NH7ydpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{SzRWlEPTB;OT62N\|gxOSEQvF2=	M1rYPXNCVkeHUh?=
SN12C	M{jsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\BTWM2OD17Lk[1N\|M5KM7:TR?=	MYjTRW5ITVJ?
KLE	NGjTNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF24fHlKSzVyPUmuO\|AxODlizszN	NYLmOXNxW0GQR1XS
EFO-21	NI\xSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LIeWlEPTB;OT63O\|M5OiEQvF2=	M2rURXNCVkeHUh?=
KYSE-70	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX62VYRXUUN3ME25Mlg5ODFzIN88US=>	NUCwbFNUW0GQR1XS
D-247MG	M{XyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfRTWM2OD1zMD6wOVY5KM7:TR?=	MX7TRW5ITVJ?
MPP-89	NILKclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLHTWM2OD1zMD6wPVQ3KM7:TR?=	MYTTRW5ITVJ?
RVH-421	NXnVbFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TXWWlEPTB;MUCuNVUxPSEQvF2=	NUTo[mlPW0GQR1XS
NCI-H460	M4X2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TNW2lEPTB;MUCuNlgxPiEQvF2=	MVLTRW5ITVJ?
NOMO-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3u1WmlEPTB;MUCuN\|U{OiEQvF2=	NYnLR\|VLW0GQR1XS
DEL	NVTIfoJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF25V\|VKSzVyPUGwMlM4QTRizszN	MXXTRW5ITVJ?
HT55	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXoenZKSzVyPUGwMlYzODVizszN	NHL2[ZpUSU6JRWK=
MC116	NFzCSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYC5eoZHUUN3ME2xNE43PjV3IN88US=>	MWjTRW5ITVJ?
BB30-HNC	NH31RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHWTWM2OD1zMD62Olkh\|ryP	M325eHNCVkeHUh?=
DJM-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPGTWM2OD1zMD62PVQ6KM7:TR?=	MlLWV2FPT0WU
ZR-75-30	M1\4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHzTWM2OD1zMD65OFQyKM7:TR?=	Mo\FV2FPT0WU
U-118-MG	M3exWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXETWM2OD1zMD65PFk3KM7:TR?=	MWjTRW5ITVJ?
MSTO-211H	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPufFJsUUN3ME2xNU4xPzF4IN88US=>	NYPTenJEW0GQR1XS
SW837	NEO2doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFzLkC5OFkh\|ryP	M4Dhd3NCVkeHUh?=
HuCCT1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnwNXB3UUN3ME2xNU4yOjhzIN88US=>	NV;6ZmtUW0GQR1XS
RCC10RGB	NIrVeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1T0c2lEPTB;MUGuNVM2KM7:TR?=	M2O2PXNCVkeHUh?=
NMC-G1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXYTWM2OD1zMT6xOFk{KM7:TR?=	NFTJVWFUSU6JRWK=
NCI-H650	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\Xc5dKSzVyPUGxMlM4QTRizszN	M2HsZnNCVkeHUh?=
HEC-1	NHPCV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFzLkSzNlgh\|ryP	NWLSVpJ{W0GQR1XS
DU-4475	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXBTWM2OD1zMT63N\|k{KM7:TR?=	M{HDXHNCVkeHUh?=
DSH1	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkL1TWM2OD1zMT63OlA3KM7:TR?=	MmH3V2FPT0WU
HCC1569	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fXS2lEPTB;MUGuO\|Y4QCEQvF2=	MWHTRW5ITVJ?
HCC1187	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXGx[XprUUN3ME2xNU45PTh6IN88US=>	NX;mS\|ZuW0GQR1XS
EW-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTFzLkm0O\|Qh\|ryP	M4LSRnNCVkeHUh?=
LB2518-MEL	NUnke3o1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvaUG9KSzVyPUGyMlA2QSEQvF2=	NF3hOYtUSU6JRWK=
KALS-1	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnY[JpKSzVyPUGyMlg2PTNizszN	MX7TRW5ITVJ?
8505C	M33WN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTF{Lki4OUDPxE1?	MYPTRW5ITVJ?
SK-N-DZ	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3:z[2lEPTB;MUOuNFQ2OyEQvF2=	NYCyeJJOW0GQR1XS
CHP-134	M3;VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LIPWlEPTB;MUOuNVE2QCEQvF2=	Mo\IV2FPT0WU
HCE-T	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjzOJJxUUN3ME2xN{4zOzZ2IN88US=>	NW\PcYpPW0GQR1XS
LB-831-BLC	NWTz[GhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmP6TWM2OD1zMz62NlQ3KM7:TR?=	NEjxPJFUSU6JRWK=
OVCAR-4	NUHKbJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF\|Lk[1NlQh\|ryP	Mo[wV2FPT0WU
SW756	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWK5SFFZUUN3ME2xN{44OjR4IN88US=>	NEDyR4hUSU6JRWK=
OCUB-M	M3G3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHxTWM2OD1zMz64NVU3KM7:TR?=	MXTTRW5ITVJ?
SW982	NFvEOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTF\|LkiyO\|Yh\|ryP	M1PNUnNCVkeHUh?=
DB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDnTWM2OD1zMz64N\|g1KM7:TR?=	Mon4V2FPT0WU
H-EMC-SS	NV7VZ5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF\|LkmxN\|kh\|ryP	M3Pnb3NCVkeHUh?=
VMRC-RCZ	M3KzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH33SZJKSzVyPUG0MlAxOTVizszN	Ml;1V2FPT0WU
CAKI-1	NVvRcHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLCTWM2OD1zND6wNVMzKM7:TR?=	MV;TRW5ITVJ?
GI-1	M3HDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TkVmlEPTB;MUSuNFY2QCEQvF2=	M3nNcXNCVkeHUh?=
Ca9-22	NXHBenRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTF2Lk[wOVQh\|ryP	NYLvNm4yW0GQR1XS
TE-5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4flc2lEPTB;MUSuO\|IxQCEQvF2=	M2XkfnNCVkeHUh?=
EFO-27	NUTG[W56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTF2Lke2NlIh\|ryP	M4TkXnNCVkeHUh?=
CAL-72	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnCTWM2OD1zND63O\|g{KM7:TR?=	NWfiWGcyW0GQR1XS
GP5d	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTF3LkC0O\|Qh\|ryP	MnjhV2FPT0WU
CAS-1	M320N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfMZ25KSzVyPUG1MlA3PiEQvF2=	M{PIXXNCVkeHUh?=
A2058	NGjk[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HpWmlEPTB;MUWuOVY{QCEQvF2=	NV7J[GtxW0GQR1XS
PANC-08-13	M3\qTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPiXmprUUN3ME2xOU43QDV7IN88US=>	MXfTRW5ITVJ?
Detroit562	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NESyZ41KSzVyPUG1MlkyOzlizszN	MUjTRW5ITVJ?
PANC-10-05	NVX0WoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXHTWM2OD1zNj6wPFIyKM7:TR?=	M1ToOHNCVkeHUh?=
KOSC-2	M3HnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGSwWopKSzVyPUG2MlEyOjVizszN	NGHpboZUSU6JRWK=
GT3TKB	M3Xq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XTNWlEPTB;MU[uNVk5OSEQvF2=	NVrveY15W0GQR1XS
KM-H2	NIPlUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLWTY5KSzVyPUG2MlM3PDZizszN	NETr[IhUSU6JRWK=
LB771-HNC	NF3XOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXtT3lKSzVyPUG2MlQ1OjJizszN	MlvnV2FPT0WU
SF268	NIi5eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzqTWM2OD1zNj60OVIh\|ryP	NWnxOJVYW0GQR1XS
OE19	M2CzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVy3cYxMUUN3ME2xOk42OjRizszN	NXr1NYpIW0GQR1XS
MLMA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTF4LkW1O\|Eh\|ryP	Mk[2V2FPT0WU
MDA-MB-231	NHf0VFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFK2SYFKSzVyPUG2MlcyOzZizszN	MVfTRW5ITVJ?
TGW	NIe4UoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF4LkixNFIh\|ryP	NYiwPY55W0GQR1XS
MDA-MB-453	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF5LkCwNFMh\|ryP	MX\TRW5ITVJ?
SNU-C2B	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTF5LkCyN\|ch\|ryP	MmPPV2FPT0WU
A427	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fJXGlEPTB;MUeuNlM{PCEQvF2=	NUfpXYMyW0GQR1XS
SK-MEL-2	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rNfGlEPTB;MUeuN\|IyOyEQvF2=	MVXTRW5ITVJ?
KURAMOCHI	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLxOYV2UUN3ME2xO{4{QDl5IN88US=>	NI\1WYZUSU6JRWK=
IST-MEL1	M2O1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nTdmlEPTB;MUeuPVE5OiEQvF2=	NXzjZ4R{W0GQR1XS
NCI-H1793	M2XOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XT[mlEPTB;MUiuNVU5OSEQvF2=	NIm2[ZNUSU6JRWK=
HCC1395	M{PmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\Lb2lEPTB;MUiuOVYyOSEQvF2=	NYD0WVF7W0GQR1XS
NUGC-3	M37Pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4n5dWlEPTB;MUiuOlU5PCEQvF2=	NYTQPG1zW0GQR1XS
BB65-RCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTF6Lk[2PUDPxE1?	MWLTRW5ITVJ?
RMG-I	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW5cYlXUUN3ME2xPE44Ozh{IN88US=>	MWLTRW5ITVJ?
LS-513	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDMVYRKSzVyPUG4MlkzOjhizszN	NWTTeIZWW0GQR1XS
MFM-223	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzXlVZUUN3ME2xPU4xPzF4IN88US=>	NILibo1USU6JRWK=
NCI-H727	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvZO4pKSzVyPUG5MlMzQTVizszN	M3fGbnNCVkeHUh?=
KP-4	NEnocGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF7Lki1N\|Eh\|ryP	MUXTRW5ITVJ?
NB13	M2TGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;6NlFKSzVyPUG5Mlg5OzlizszN	NESyco5USU6JRWK=
UACC-893	NYXZVYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF7Lkm3OVch\|ryP	NIDPSZpUSU6JRWK=
HT-1197	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m4RmlEPTB;MkCuNlk2QCEQvF2=	M4noW3NCVkeHUh?=
NCI-H2029	M1fzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDETWM2OD1{MD6zNlY3KM7:TR?=	Mly0V2FPT0WU
GI-ME-N	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzqfVJPUUN3ME2yNE4{Ozd\|IN88US=>	MXvTRW5ITVJ?
OVCAR-3	NGTvPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJyLkW4NlIh\|ryP	NIW4TYZUSU6JRWK=
HD-MY-Z	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWX1c\|JEUUN3ME2yNU4{Pjl4IN88US=>	MojYV2FPT0WU
NTERA-S-cl-D1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjiTWM2OD1{MT62O\|IzKM7:TR?=	MVXTRW5ITVJ?
SCH	NEXINllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTJ{LkS5OkDPxE1?	NWrVUFVpW0GQR1XS
KARPAS-299	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;Y[5ZIUUN3ME2yN{4{QDh5IN88US=>	NUC4d4hnW0GQR1XS
NCI-H1650	NFfNbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmixTWM2OD1{Mz65NlQyKM7:TR?=	MoL1V2FPT0WU
ACHN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnkWIZKSzVyPUK0MlQ3PTZizszN	M{\GOHNCVkeHUh?=
M059J	NVe4VZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\aNYRKSzVyPUK0MlU3OzRizszN	MmTwV2FPT0WU
AM-38	NGLIWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3exXGlEPTB;MkWuOFgyKM7:TR?=	M1\W[XNCVkeHUh?=
KG-1	NEfQfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnFXZVKSzVyPUK1MlU1QTRizszN	M2rHdHNCVkeHUh?=
COLO-824	NEPWR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnuPW5TUUN3ME2yOU42PTl7IN88US=>	M3fGOHNCVkeHUh?=
NCI-H1155	NIG0TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGWzeGxKSzVyPUK1MlU5PDdizszN	MmTCV2FPT0WU
NCI-H441	NXK5NYxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zYXmlEPTB;MkWuO\|Q3PSEQvF2=	M1zZfXNCVkeHUh?=
J-RT3-T3-5	NWSyOodkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LnNGlEPTB;Mk[uN\|AzPyEQvF2=	NUPiOVI2W0GQR1XS
JEG-3	NUPl[G1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJ4Lk[4NFUh\|ryP	NXnOXIl[W0GQR1XS
RKO	NHnDU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJ4Lke2N\|Ih\|ryP	MmexV2FPT0WU
CAL-85-1	NV7HPIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrzTWM2OD1{Nz6yNVE5KM7:TR?=	MXPTRW5ITVJ?
CAL-120	M1u3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XvO2lEPTB;MkeuOlkyPCEQvF2=	M4ntTHNCVkeHUh?=
NCI-H2452	M4jGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm5TWM2OD1{Nz63O\|E3KM7:TR?=	NWHMdoxoW0GQR1XS
NCI-H1395	NHH0c2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFm5dYNKSzVyPUK3Mlc5OzNizszN	NU[ycWxoW0GQR1XS
KYSE-450	NI[yN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmm1TWM2OD1{Nz65PFYzKM7:TR?=	MV;TRW5ITVJ?
S-117	MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHjWVFKSzVyPUK5MlM5PTdizszN	MmLKV2FPT0WU
SW13	NVXCdFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnGNHFRUUN3ME2yPU45PTF7IN88US=>	MYPTRW5ITVJ?
ES3	M1\mcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfHWnR2UUN3ME2zNE4{PzN\|IN88US=>	MVPTRW5ITVJ?
HCT-116	M2L1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;ITWM2OD1\|MD61OVU1KM7:TR?=	NXXmNJpWW0GQR1XS
NCI-H1693	NWi0fXVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTNyLkW5OFIh\|ryP	MnT5V2FPT0WU
VM-CUB-1	NFrMN\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;GWmlEPTB;M{CuOlQyOyEQvF2=	MUPTRW5ITVJ?
NCI-H2170	M4XERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPWTllyUUN3ME2zNU42Pzh2IN88US=>	MmrtV2FPT0WU
ALL-PO	NUCxWXozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\nTWM2OD1\|MT64OFI5KM7:TR?=	MnXBV2FPT0WU
NCI-H661	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[4TWM2OD1\|Mj6wOlI{KM7:TR?=	M1znWXNCVkeHUh?=
NCI-H2347	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXXWoVKSzVyPUOyMlQ5OzdizszN	NG\3ZmhUSU6JRWK=
FTC-133	Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{S3RWlEPTB;M{KuO\|A3KM7:TR?=	MmrGV2FPT0WU
COLO-829	NUXuS4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIT0UIdKSzVyPUOzMlM1PjdizszN	NFLuTldUSU6JRWK=
GOTO	NFPybXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DyeWlEPTB;M{OuOVI2QCEQvF2=	NELIRppUSU6JRWK=
YAPC	M3L3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\i[2lEPTB;M{OuPFE2QSEQvF2=	NVrmUHE2W0GQR1XS
LCLC-103H	M1TiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHNcWM3UUN3ME2zOE4yPjJ2IN88US=>	NHjscGNUSU6JRWK=
SiHa	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;MXFJrUUN3ME2zOE4{QDF5IN88US=>	MUnTRW5ITVJ?
LK-2	NUHhVlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfUTWM2OD1\|ND61O\|A5KM7:TR?=	M3;rcHNCVkeHUh?=
KP-N-YS	NILTRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL3dXBKSzVyPUO0MlczODJizszN	M4nHNHNCVkeHUh?=
NCI-SNU-1	M3G5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTN3LkG3PUDPxE1?	NGjKUYJUSU6JRWK=
KNS-81-FD	M3nudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\wWnlKSzVyPUO1MlY3OyEQvF2=	MVPTRW5ITVJ?
SCC-9	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTN4LkexOFYh\|ryP	MnX1V2FPT0WU
SH-4	NFXBcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWeyd5E2UUN3ME2zOk44OyEQvF2=	NWPLWlQyW0GQR1XS
HCC-1954	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mor6TWM2OD1\|Nz6yO\|I6KM7:TR?=	NIT3cllUSU6JRWK=
BALL-1	NV;RdpF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrUTWM2OD1\|Nz61N\|E3KM7:TR?=	MVjTRW5ITVJ?
BE-13	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\vXWhKSzVyPUO3MlcxOThizszN	MVrTRW5ITVJ?
COLO-678	NGPOdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPhcpFWUUN3ME2zO{46PDN5IN88US=>	MkTjV2FPT0WU
SK-MEL-3	NGDldlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TGe2lEPTB;M{iuNlM6PyEQvF2=	MnTUV2FPT0WU
OAW-28	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zq[GlEPTB;M{iuOlM6KM7:TR?=	MmC2V2FPT0WU
CAMA-1	NF6xcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoK2TWM2OD1\|OD65OlkyKM7:TR?=	NWK2dGIzW0GQR1XS
C2BBe1	NFjzeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILId4hKSzVyPUO5MlgyQCEQvF2=	M3iwOnNCVkeHUh?=
A3-KAW	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTRyLkO2OlEh\|ryP	NYPtWZl[W0GQR1XS
SK-MEL-24	NXXvdGJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTRyLkW5N\|Eh\|ryP	Mlq2V2FPT0WU
KYSE-140	M{S0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\vTWM2OD12MD63NVY2KM7:TR?=	MVPTRW5ITVJ?
MOLT-16	MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TXZWlEPTB;NEGuNVU{PiEQvF2=	MX;TRW5ITVJ?
CFPAC-1	NEnPOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPwTWM2OD12Mj61NlEyKM7:TR?=	M13mUnNCVkeHUh?=
NB14	NU\6PVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT6VGZKSzVyPUSyMlcxOjdizszN	M4q3dHNCVkeHUh?=
COLO-792	NYXRb3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTR{Lki5OlEh\|ryP	M3fxU3NCVkeHUh?=
RH-1	NV;E[FRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz6TWM2OD12Mz60PFM3KM7:TR?=	NV7zNoRXW0GQR1XS
NCI-H522	M3LHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDQR29uUUN3ME20OE4{PTZ6IN88US=>	NFfhVItUSU6JRWK=
Ca-Ski	NIDGeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmT1TWM2OD12ND64NVE1KM7:TR?=	MUTTRW5ITVJ?
KGN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF62dHRKSzVyPUS4MlMxPjNizszN	NWC2SZdVW0GQR1XS
UACC-62	NEDFfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXSTWM2OD12OD60NFczKM7:TR?=	MUTTRW5ITVJ?
NCI-H358	NXfTVo85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrEU5N3UUN3ME20PU4{ODF6IN88US=>	MW\TRW5ITVJ?
LS-411N	NXfKR\|NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DYV2lEPTB;NEmuN\|EyQCEQvF2=	MXzTRW5ITVJ?
IST-MES1	M{\4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrxfJFKSzVyPUS5MlU3OjVizszN	M3nHbHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Formulation: Dissolved in 10% DMSO, 5% Tween 20, 85% water Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RG7321

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 291 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 291 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)